Home
Your Profile
Become a Member/Get Newsletter
Contact Us
Recent Updates
Current Papers
Search All Papers
Search Comments
Research News
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Tech Corner
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by
NARSAD
, the Brain and Behavior Research Fund, and was created with funding from the
U.S. National Institute of Mental Health
.
Printable version
SZGene - Gene overview of all published SZ-association studies for DRD2
Gene:
DRD2
(D2R; D2DR)
View on PDGene
Protein:
dopamine receptor D2
(seven transmembrane helix receptor)
Chromosome:
11
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 21 October 2010
1. Case-Control Studies (by ethnic group)
SZ Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Asherson, 1994
UK
CL
1
(detail)
112
(-)
IIIR
-
-
64
(-)
-
Negative
Bertolino, 2008
Italy
CL
3
(detail)
196
(25%)
IV
-
33.5 + 12.8
(-)
249
(61%)
36.6 + 11.5
(-)
Positive
Betcheva, 2009
Bulgaria (I)
CL
4
(detail)
185
(-)
IV
-
-
184
(-)
-
Positive
Betcheva, 2009
Bulgaria (II)
CL
2
(detail)
70
(-)
IV
-
-
372
(-)
-
Positive
Breen, 1999
UK
CL
1
(detail)
439
(-)
M
-
-
437
(-)
-
Positive
Campion, 1994
France
CL
1
(detail)
80
(-)
IIIR
-
-
80
(-)
-
Negative
Comings, 1991
USA
CL
1
(detail)
87
(-)
III
-
-
314
(-)
-
Negative
Crawford, 1996
USA
CL
1
(detail)
84
(-)
IIIR
-
-
81
(-)
-
Negative
Dollfus, 1996
France
CL
1
(detail)
62
(-)
M
-
-
161
(-)
-
Negative
Dubertret, 2001
Overlaps with
Dubertret, 2010
CL
2
(detail)
50
(26%)
IV
20.6 + 3.1
(-)
-
50
(22%)
-
n.a.
Dubertret, 2004
Overlaps with
Dubertret, 2010
CL
6
(detail)
103
(21%)
IV
20.7 + 8
(-)
-
83
(19%)
-
n.a.
Dubertret, 2010
France
CL
8
(detail)
252
(40%)
IV
27.5
(-)
40.4
(-)
142
(54%)
73.6 + 8.3
(-)
Positive
Hall, 2007
Overlaps with
Jonsson, 2003
CL
1
(detail)
103
(38%)
M
-
42.4 + 11.5
(-)
89
(33%)
39.2 + 11.5
(-)
n.a.
Hanninen, 2006
Finland
CL
1
(detail)
188
(45%)
IV
27 + 8.9
(-)
43.1 + 12
(18-76)
384
(46%)
44.4 + 11.2
(19-65)
Positive
Hoenicka, 2006
Spain
CL
1
(detail)
131
(42%)
IV
-
-
364
(-)
-
Positive
Hoogendoorn, 2005
Netherlands
CL
2
(detail)
208
(-)
IV
-
-
288
(-)
-
Negative
Jonsson, 1996
Sweden
CL
1
(detail)
118
(36%)
IIIR
-
45.8
(20-90)
78
(42%)
38.7
(29-56)
Negative
Jonsson, 1999
Sweden
CL
1
(detail)
129
(36%)
IIIR
-
44.6 + 17.3
(-)
179
(52%)
45.3 + 15.9
(-)
Positive
Jonsson, 2003
Sweden
CL
1
(detail)
173
(37%)
M
-
44 + 15.6
(-)
236
(37%)
39.8 + 10.3
(-)
Positive
Kampman, 2003
Finland
CL
1
(detail)
93
(-)
IV
-
-
94
(-)
-
Negative
Lafuente, 2008
Spain
CL
3
(detail)
243
(46%)
IV
-
34 + 13
(-)
291
(62%)
61.7 + 11
(-)
Positive
Laurent, 1994
France
CL
1
(detail)
113
(30%)
IIIR
-
42 + 0.6
(-)
184
(40%)
49 + 0.5
(-)
Negative
Lawford, 2005
Australia
CL
1
(detail)
153
(13%)
IV
-
36.2 + 12.3
(18-65)
148
(29%)
36.8 + 12.8
(-)
Positive
Li, 1998
UK
CL
1
(detail)
151
(56%)
M
-
29.4 + 10.9
(15-65)
145
(158%)
-
Negative
Mas, 2009
Spain
CL
13
(detail)
159
(-)
IV
-
-
373
(54%)
51.9 + 19
(-)
Negative
Meda, 2009
USA
CL
2
(detail)
31
(-)
IV
-
-
35
(-)
-
Negative
Monakhov, 2008
Russia
CL
3
(detail)
311
(48%)
IV
25.4 + 8.9
(-)
35.3 + 12.5
(-)
364
(62%)
31.7 + 12.7
(-)
Positive
Nothen, 1993
Germany
CL
1
(detail)
60
(33%)
IIIR
25.2 + 8
(14-46)
34.8 + 11
(-)
60
(47%)
28.2 + 5.2
(-)
Negative
Nothen, 1994
Germany
CL
1
(detail)
179
(-)
III
-
-
138
(-)
-
Negative
Parsons, 2007
Spain
CL
2
(detail)
119
(34%)
IV
-
41.2 + 13.9
(-)
165
(51%)
26.8 + 5.4
(-)
Positive
Saiz, 2009
Spain
CL
1
(detail)
288
(40%)
IV
-
36.3 + 12.4
(-)
421
(49%)
40.6 + 11.3
(-)
Positive
Sanders, 1993
USA
CL
1
(detail)
55
(9%)
IIIR
26 + 8
(13-56)
44 + 14
(21-71)
51
(6%)
60 + 10
(37-78)
Negative
Sanders, 2008
USA, Australia
CL
31
(detail)
1870
(31%)
IV
-
-
2002
(53%)
-
Negative
Sasaki, 1996
USA, Canada, Italy
CL
1
(detail)
273
(33%)
IIIR
-
32 + 9
(-)
255
(50%)
-
Negative
Serretti, 2000
Italy
CL
1
(detail)
366
(-)
IV
-
-
267
(52%)
46.6 + 15.9
(-)
Negative
Shaikh, 1994
UK
CL
1
(detail)
140
(-)
III
-
-
100
(-)
-
Positive
Sobell, 1994
USA
CL
1
(detail)
338
(-)
III
-
-
1914
(-)
-
Negative
Spurlock, 1998
UK
CL
1
(detail)
97
(-)
IIIR
-
-
106
(-)
-
Negative
Spurlock, 1998
Italy
CL
1
(detail)
103
(-)
IIIR
-
-
96
(-)
-
Negative
Spurlock, 1998
Ireland
CL
1
(detail)
34
(-)
IIIR
-
-
89
(-)
-
Negative
Spurlock, 1998
Austria
CL
1
(detail)
72
(-)
IIIR
-
-
57
(-)
-
Negative
Stober, 1998
Germany
CL
1
(detail)
260
(40%)
10
26.9 + 9.4
(-)
-
290
(45%)
29.3 + 9.7
(-)
Negative
Talkowski, 2008
USA
CL
5
(detail)
328
(-)
IV
-
-
501
(-)
-
Negative
Tallerico, 1999
USA, Canada
CL
1
(detail)
50
(-)
IIIR
-
-
51
(-)
-
Negative
Verga, 1997
Italy
CL
1
(detail)
103
(41%)
IIIR
22.8 + 7.1
(-)
37.9 + 10.5
(-)
97
(51%)
53.2 + 16.4
(-)
Negative
Virgos, 2001
Spain
PO
1
(detail)
262
(40%)
9
-
61.4
(19-90)
278
(39%)
54.2
(21-90)
Positive
Asian
Arinami, 1994
Overlaps with
Arinami, 1996
CL
1
(detail)
156
(37%)
IIIR
-
48.1
(17-75)
300
(-)
45.2
(31-60)
n.a.
Arinami, 1996
Overlaps with
Itokawa, 1993
CL
1
(detail)
291
(-)
M
-
-
579
(-)
-
Trend
Arinami, 1997
Japan
CL
2
(detail)
260
(46%)
IIIR
22.4
(12-39)
44.4
(19-81)
312
(45%)
48.7
(29-75)
Positive
Chen, 1996
Taiwan
CL
1
(detail)
114
(50%)
IIIR
-
40
(-)
88
(60%)
27.5
(-)
Negative
Fan, 2009
China
CL
3
(detail)
421
(-)
IV
-
30.7 + 10.7
(15-70)
404
(-)
28.1 + 8.1
(16-60)
Positive
Fujiwara, 1997
Japan
CL
1
(detail)
52
(-)
M
-
-
26
(-)
-
Negative
Harano, 1997
Japan
CL
1
(detail)
70
(34%)
IIIR
-
47 + 10
(-)
101
(54%)
67 + 15
(-)
Negative
Hattori, 1994
Japan
CL
1
(detail)
100
(50%)
IIIR
-
-
100
(50%)
-
Negative
Himei, 2002
Japan
CL
2
(detail)
190
(37%)
IV
-
53.1 + 11.5
(-)
103
(49%)
33.1 + 10.8
(-)
Negative
Hokyo, 2010
Japan
CL
2
(detail)
407
(42%)
IV
-
54.7
(-)
384
(64%)
40.1
(-)
Negative
Hori, 2001
Japan
CL
2
(detail)
241
(49%)
IV
-
52.7 + 11.5
(-)
201
(50%)
54.7 + 6.8
(-)
Negative
Inada, 1999
Japan
CL
1
(detail)
234
(-)
IIIR
-
-
94
(-)
-
Positive
Itokawa, 1993
Japan
CL
1
(detail)
50
(42%)
IIIR
-
-
110
(-)
-
Negative
Kaneshima, 1997
Japan
CL
1
(detail)
78
(55%)
IV
-
36.3 + 10.1
(19-68)
112
(68%)
23 + 2.1
(18-30)
Negative
Luu, 2008
Taiwan
CL
1
(detail)
211
(47%)
IV
-
43
(-)
201
(55%)
42
(-)
Negative
Morimoto, 2002
Japan
CL
1
(detail)
48
(-)
III
-
-
48
(-)
-
Negative
Nanko, 1994
Overlaps with
Hattori, 1994
CL
1
(detail)
100
(50%)
IIIR
-
-
100
(50%)
-
n.a.
Ohara, 1996
Japan
CL
1
(detail)
153
(50%)
IV
26.3 + 9.5
(-)
46.3 + 16
(-)
121
(58%)
34.4 + 14.1
(-)
Negative
Ohara, 1998
Japan
CL
1
(detail)
170
(48%)
IV
26 + 9.7
(-)
43.5 + 16.1
(-)
121
(58%)
35.4 + 14.2
(-)
Positive
Tanaka, 1996
Japan
CL
1
(detail)
106
(48%)
IIIR
-
44.7 + 11.8
(15-70)
106
(41%)
45.8 + 25
(22-86)
Negative
Other/Mixed
Behravan, 2008
Iran
CL
2
(detail)
38
(55%)
IV
-
42 + 12
(-)
63
(62%)
46 + 18
(-)
Negative
Cordeiro, 2009
Brazil
CL
1
(detail)
229
(35%)
IV
-
27.2 + 7.5
(19-64)
733
(32%)
31.8 + 9.1
(18-79)
Positive
Gejman, 1994
USA
CL
1
(detail)
106
(-)
M
-
-
125
(-)
-
Negative
Gupta, 2009
India
CL
8
(detail)
254
(39%)
IV
-
29.2 + 7.6
(-)
225
(38%)
31 + 11
(-)
Positive
Kukreti, 2006
Overlaps with
Gupta (2009)
CL
2
(detail)
101
(45%)
IV
25.3 + 7.3
(-)
-
145
(-)
-
n.a.
Pal, 1995
India
CL
1
(detail)
156
(37%)
IIIR
-
-
300
(-)
-
Positive
Srivastava, 2010
India
CL
5
(detail)
215
(48%)
IV
21.4 + 6.1
(-)
29.3 + 8.9
(-)
215
(40%)
34.6 + 12.4
(-)
Positive
Vijayan, 2007
India
CL
5
(detail)
213
(62%)
IV
24.4 + 8
(-)
34.4 + 10.8
(-)
196
(-)
-
Positive
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Ambrosio, 2004
Portugal
1
(detail)
90
90
(36%)
IV
-
-
180
(50%)
-
Negative
Dubertret, 2001
Overlaps with
Dubertret, 2010 (CC)
2
(detail)
50
50
(26%)
IV
-
-
100
(50%)
-
n.a.
Dubertret, 2004
Overlaps with
Dubertret, 2010 (CC)
4
(detail)
103
103
(21%)
IV
20.7 + 8
(-)
-
206
(50%)
-
n.a.
Dubertret, 2010
Overlaps with
Dubertret, 2010 (CC)
4
(detail)
108
108
(20%)
IV
-
-
-
-
Positive
Fallin, 2005
USA
5
(detail)
263
274
(26%)
IV
19.5 + 4.5
(-)
-
548
(50%)
-
Negative
Laurent, 1994
France
1
(detail)
51
-
IIIR
-
-
-
-
Negative
Schindler, 2002
Portugal
1
(detail)
78
78
(38%)
IV
-
-
156
(50%)
-
Positive
Talkowski, 2008
USA
5
(detail)
150
150
(50%)
IV
-
-
300
(50%)
-
Negative
Asian
Glatt, 2008
Taiwan
24
(detail)
616
1214
(-)
IV
-
-
1194
(-)
-
Positive
Li, 1998
China
1
(detail)
229
229
(37%)
M
-
29.4 + 10.9
(15-65)
458
(50%)
-
Negative
Other/Mixed
Fanous, 2004
USA
1
(detail)
544
(-)
IIIR
-
-
730
(-)
-
Negative
Goldman, 1997
USA
1
(detail)
5
(20%)
IIIR
-
-
455
(-)
-
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine SZ diagnosis -> "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-)
: Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
SZGene Stats
Studies: 1727
Genes: 1008
Polymorphisms: 8788
Meta-analyses: 287
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
SRF News
SRF Comments
Text Size
Reset Text Size
Email this page
Research Participants
Collaborators
Copyright © 2005-2024 Schizophrenia Research Forum
Privacy Policy
Disclaimer
Disclosure
Copyright